Patent allowance for ion exchange resin formulation of benzonatate Alitair Pharmaceuticals, Inc., today announced that it received a Notice of Allowance from america Patent and Trademark Workplace for its ion exchange resin formulation of benzonatate. The patent includes specific promises for eliminating or reducing the choking hazard associated with standard liquid formulations of benzonatate. Our oral solid ion exchange resin formulation provides been proven to reduce or eliminate the choking hazard, stated Alitair President and CEO, William W. Howard, Ph.D. Our proprietary technology allows us to bind benzonatate to a resin particle, which represents a completely novel formulation approach and resolves this significant security issue. This Notice of Allowance marks a significant milestone in our benzonatate product development strategy and may be the main element to benzonatate becoming a successful Rx-to-OTC switch candidate, continued Howard.Almost 35 percent of significantly injured kids 5 years and more youthful were undertriaged, and 25 percent of children 6-17 years older had been undertriaged. Related StoriesBoston Children's Medical center selects Vijay G. Sankaran to get Rising Star AwardCHOP's Buerger Center for Advanced Pediatric Treatment celebrates grand openingNew UCLA research looks at primary care medical home in reducing childrens' repeat appointments to hospitalsDr. Xiang said a true number of factors might explain the high numbers of undertriaged patients.